News

The FDA has expanded the approved use of Seattle Genetics’ Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma.
Top news of the day from across the health care landscape.
Top news of the week from Specialty Pharmacy Times.
The statement is intended to serve as a discussion guide for the risk factors, diagnosis, treatment and prevention of the disease.
NYU Langone Health discusses the challenges and benefits involved in starting or expanding a health system’s specialty pharmacy.
Study evaluates the association between body mass index in late adolescence and the incidence of pancreatic cancer in adulthood.
The FDA granted the designation to brentuximab vedotin (Adcetris) for this indication in combination with cyclophosphamide, doxorubicin, and prednisone.

Product News

Granix is a human granulocyte factor produced in a bioreactor using recombinant DNA technology.
Complera treats HIV infection in previously untreated adults with a viral load of 100,000 copies/mL or less.
Repatha (evolocumab) treats primary hyperlipidemia in combination with dietary measures and maximally tolerated doses of statins.
Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) is approved for treatment of HIV-1 infection.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$